Key facts
- This page summarizes Heidi Fields's Form 4 filing for Phathom Pharmaceuticals, Inc. (PHAT).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 27 May 2022, 16:43.
Heidi Fields - 25 May 2022 Form 4 Insider Report for Phathom Pharmaceuticals, Inc. (PHAT)
- Reporting relationship
- Director
- Issuer ticker
- PHAT
- Reported as of
- 25 May 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 27 May 2022, 16:43:54 UTC
- Prior SEC filing
- 21 Mar 2022
- Next SEC filing
- 14 Jun 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Larry Miller, Attorney-in-Fact for Heidi Kunz
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Heidi Fields filed Form 4 for Phathom Pharmaceuticals, Inc. (PHAT) on 27 May 2022.
Change
- Previous filing in this sequence was filed on 21 Mar 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
PHAT
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +15,000
- Change %
- Price
- $0.000000
- Shares after
- 15,000
- Date
- 25 May 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 15,000
- Exercise price
- $7.40
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. The option shall vest and/or become exercisable on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to Reporting Person's continuing in service on the Board through such vesting date.